ACTU

Business Context and Reporting Period

Company: Actuate Therapeutics, Inc. (Nasdaq: ACTU)
Reporting Period: Fiscal Year Ended December 31, 2024 (Form 10-K)
Business Overview: Actuate is a clinical-stage biopharmaceutical company developing elraglusib, a GSK-3β inhibitor, for the treatment of high-impact cancers. The company recently completed its Initial Public Offering (IPO) in August 2024.

Key Financial Metrics

Note: The company has no revenue and operates at a loss. The 2024 net loss includes non-cash charges related to the fair value adjustment of related party convertible notes ($2.2 million) and warrant liability changes.

Material Changes vs. Prior Period

• Capital Raise: Completed an IPO in August 2024, raising approximately $22 million in net proceeds. Issued 3.22 million shares of common stock.
• Equity Conversion: All redeemable convertible preferred stock and related party convertible notes converted to common stock upon IPO closing.
• Expense Trends: Research and Development (R&D) expenses decreased by $3.0 million year-over-year, primarily due to reduced preclinical studies and lower CRO costs. General and Administrative (G&A) expenses increased by $3.2 million, driven by stock-based compensation ($1.6 million) and public company costs (audit, legal, insurance).
• Liquidity: Cash position improved significantly from $3.0 million to $8.6 million due to IPO proceeds and bridge financing, though the company faces a "substantial doubt" regarding its ability to continue as a going concern without further funding.

Guidance, Outlook, and Clinical Highlights

Clinical Progress (Elraglusib)

• Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC): Interim data from the Phase 2 Actuate-1801 Part 3B trial (cutoff Nov 15, 2024) showed statistically significant improvements in the elraglusib + GnP arm versus GnP alone:
  • 1-Year Survival: 43.6% vs. 22.5% (p=0.002).
  • Median Overall Survival (mOS): 9.3 months vs. 7.2 months (Hazard Ratio 0.63, p=0.016).
  • Objective Response Rate (ORR): 27.7% vs. 20.5%.
• Ewing Sarcoma: Positive exploratory data in pediatric patients; FDA granted Rare Pediatric Disease Designation (RPDD) in October 2024.
• Oral Tablet: Developing an oral formulation (Actuate-2401) to expand indications; Phase 1 planned subject to funding.

Outlook and Risks

• Funding Requirement: Management estimates current cash will not satisfy operational requirements for 12 months. Additional capital is required to advance Phase 3 planning and commercialization.
• Regulatory Path: Plans to meet with the FDA in 2025 to discuss Phase 3 design and potential registration based on Phase 2 data.
• Risks: Substantial doubt about going concern status; reliance on single product candidate; potential dilution from future financing; and the risk that interim clinical data may change upon final analysis.

Investor Verification Checklist

• Cash Runway: Verify the timeline for the next capital raise given the "substantial doubt" going concern qualification and $8.6M cash balance.
• Clinical Data Finalization: Confirm the final top-line results of the Actuate-1801 Part 3B trial (expected Q2 2025) to validate the interim survival statistics.
• Debt Obligations: Review the terms of the UIC license agreement, specifically the deferred amount of ~$405k plus accrued interest, and any triggers for immediate payment upon financing milestones.
• Ownership Structure: Note that Bios Equity Affiliated Funds beneficially own approximately 51% of the outstanding common stock, creating significant control concentration.
• Manufacturing Supply Chain: Assess risks related to the drug substance (DS) manufacturer located in China and potential geopolitical impacts on supply.